Clinical Observation of Taxol Combined with Cisplatin Neoadjuvant Chemotherapy in the Treatment of Esophageal Cancer
10.6039/j.issn.1001-0408.2016.18.17
- VernacularTitle:紫杉醇联合顺铂新辅助化疗用于进展期食管癌的临床观察
- Author:
Huilai LYU
;
Li ZHANG
;
Shiwang WEN
;
Yuefeng ZHANG
;
Yong LI
;
Ziqiang TIAN
- Publication Type:Journal Article
- Keywords:
Esophageal carcinoma;
Taxol;
Cisplatin;
Neoadjuvant chemotherapy;
Tumor markers;
Efficacy;
safety
- From:
China Pharmacy
2016;27(18):2500-2502
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe the clinical efficacy of taxol combined with cisplatin neoadjuvant chemotherapy in the treatment of esophageal cancer and effects on serum tumor markers in patients with esophageal cancer. METHODS:100 patients with esophageal cancer were randomly divided into control group(50 cases) and observation group(50 cases). Observation group was given taxol+Cisplatin injection(TP)neoadjuvant chemotherapy,given 175 mg/m2 taxol by intravenous infusion,d1-5. And ev-ery 5 d was a treatment course,the regimen was adjusted based on patients’efficacy;control group was given conventional sur-gery and TP after surgery,the same usage and dosage as observation group,it lasted for 4 courses. Clinical efficacy,high mobility protein B1(HMGB1),carcinoembryonic antigen (CEA) and squamous cell carcinoma antigen (SCC-Ag) level in 2 groups before and after treatment were observed,objective response rate,disease control rate,the incidence of toxicity and severe toxicity,inci-dence of postoperative complications and survival rate of postoperative 1,3 and 5 years were recorded. RESULTS:After treatment, objective response rate in observation group was significantly higher than control group,HMGB1,CEA and SCC-Ag levels were significantly lower than before and control group,HMGB1 and CEA levels in control group were significantly lower than before, the differences were statistically significant(P<0.05);there were no significant differences in the disease control rate,chemothera-py-related toxicity,severe toxicity,incidence of postoperative complications,survival rate of postoperative 1,3 and 5 years and the median survival time between 2 groups(P>0.05). CONCLUSIONS:Taxol combined with cisplatin neoadjuvant chemotherapy can significantly improve the efficacy of patients with esophageal cancer and reduce the levels of cancer-related indicators,with good safety.
